The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

FGF3  -  fibroblast growth factor 3

Homo sapiens

Synonyms: FGF-3, Fibroblast growth factor 3, HBGF-3, Heparin-binding growth factor 3, INT2, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of FGF3


Psychiatry related information on FGF3

  • A probe specific for the INT-2 gene was labelled with [alpha-32P]dCTP and a probe to beta-actin, the control locus, was labelled with [alpha-35S]dATP [6].

High impact information on FGF3

  • Multipoint analysis yielded a maximum Lod score of 9.3 in the interval between markers INT2 and D11S871 [7].
  • Absence of endogenous TRP-2-INT2 expression in melanocytes was also confirmed by lack of recognition of HLA-A*68011-transduced, TRP-2(+) melanocyte lines by CTL 128 [8].
  • The cDNA encoding this antigen is composed of a partially spliced form of the melanocyte differentiation antigen tyrosinase-related protein (TRP)-2, containing exons 1-4 with retention of intron 2 and part of intron 4 (TRP-2-INT2) [8].
  • Quantitative reverse transcription PCR analysis carried out on total and/or cytoplasmic mRNA demonstrated that, in contrast to the fully spliced TRP-2 mRNA expressed in melanomas, normal skin melanocytes, and retina, the TRP-2-INT2 mRNA could be detected at significant levels in melanomas but not in normal cells of the melanocytic lineage [8].
  • In the present study, amplification of the proto-oncogenes Her-2/neu (also known as ERBB2) and INT2 was studied in primary tumor specimens from 72 premenopausal women and was related to starting age of oral contraceptive use and other reproductive risk factors [9].

Chemical compound and disease context of FGF3


Biological context of FGF3


Anatomical context of FGF3

  • NoBP overexpression conferred a proliferating effect onto NIH 3T3 cells and can counteract the inhibitory effect of nuclear FGF3, suggesting a role of NoBP in controlling proliferation in cells [12].
  • Using a novel technique for gene transfer into chicken embryos, we have readdressed the role of FGF3 during inner ear development in avians [15].
  • Nodular lesions developed at the injection sites in all seven mice injected with the F3-1 cell clone, which showed high expression of FGF3, and in two out of six mice injected with the F3-2 cell clone, which expressed a low level of FGF3 [16].
  • The FGF-3 gene is constitutively expressed in tumorigenic clones from the SW613-S human colon carcinoma cell line but is silent in non-tumorigenic clones [17].
  • HST-1 and INT-2 genes which is a member of fibroblast growth factor gene family, are amplified in approximately 50% of primary tumors and all the metastatic tumors of esophageal carcinomas [18].

Associations of FGF3 with chemical compounds

  • Analysis of secreted mutant mouse FGF3 confirmed an additional NH2-terminal processing at the corresponding sequence motif [19].
  • Int-2/FGF3 gene amplications were good indicators of prognosis, especially in premenopausal patients, and also in lymph-node-positive and steroid-receptor-negative patients [20].
  • Moreover, the relationship between progestin use and early abortion and amplification of the INT2 gene is biologically plausible [9].
  • The region of overlap of the allelic losses in the MENI-associated tumors enables us to place the MENI gene between PGA centromerically and INT2 telomerically, a region spanning about 7.5 cM [21].

Regulatory relationships of FGF3


Other interactions of FGF3

  • No expression of FGF3 or FGF4 was detected [1].
  • Genes contained in the consensus regions were MYC (8q24), EGFR (7p12.3), and FGF3 (11q13) [23].
  • Ectopic expression of FGF3 also influences the formation of the normal orthotopic inner ear, whereas another member of the FGF family, FGF2, shows no effects on inner ear induction [15].
  • We have thus undertaken fine-scale mapping of a 3.2-Mb region flanked by ACTN3 and FGF3 [24].
  • However, in the node-negative and ER-positive subgroups, there was a trend for an increased relapse rate in patients with INT-2 or CCND1 amplification [5].

Analytical, diagnostic and therapeutic context of FGF3


  1. Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Ropiquet, F., Giri, D., Kwabi-Addo, B., Mansukhani, A., Ittmann, M. Cancer Res. (2000) [Pubmed]
  2. Amplified region of chromosome band 11q13 in breast and squamous cell carcinomas encompasses three CpG islands telomeric of FGF3, including the expressed gene EMS1. Brookes, S., Lammie, G.A., Schuuring, E., de Boer, C., Michalides, R., Dickson, C., Peters, G. Genes Chromosomes Cancer (1993) [Pubmed]
  3. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Mayr, D., Kanitz, V., Anderegg, B., Luthardt, B., Engel, J., Löhrs, U., Amann, G., Diebold, J. Am. J. Clin. Pathol. (2006) [Pubmed]
  4. Fibroblast growth factors and their receptors in parathyroid disease. Lambert, D., Eaton, C.L., Harrison, B.J. World journal of surgery. (1998) [Pubmed]
  5. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Seshadri, R., Lee, C.S., Hui, R., McCaul, K., Horsfall, D.J., Sutherland, R.L. Clin. Cancer Res. (1996) [Pubmed]
  6. Quantification of oncogene dosage in tumours by simultaneous dual-label hybridization. Stickland, J.E., Tomlinson, I.P., Ramshaw, A.L., Bromley, L., Potter, C.G., McGee, J.O. Oncogene (1993) [Pubmed]
  7. Genetic linkage of vitelliform macular degeneration (Best's disease) to chromosome 11q13. Stone, E.M., Nichols, B.E., Streb, L.M., Kimura, A.E., Sheffield, V.C. Nat. Genet. (1992) [Pubmed]
  8. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. Lupetti, R., Pisarra, P., Verrecchia, A., Farina, C., Nicolini, G., Anichini, A., Bordignon, C., Sensi, M., Parmiani, G., Traversari, C. J. Exp. Med. (1998) [Pubmed]
  9. Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones. Olsson, H., Borg, A., Fernö, M., Ranstam, J., Sigurdsson, H. J. Natl. Cancer Inst. (1991) [Pubmed]
  10. Loss of heterozygosity of markers on chromosome 11 in tumors from patients with multiple endocrine neoplasia syndrome type 1. Radford, D.M., Ashley, S.W., Wells, S.A., Gerhard, D.S. Cancer Res. (1990) [Pubmed]
  11. RAAS polymorphisms alter the acute blood pressure response to aerobic exercise among men with hypertension. Blanchard, B.E., Tsongalis, G.J., Guidry, M.A., Labelle, L.A., Poulin, M., Taylor, A.L., Maresh, C.M., Devaney, J., Thompson, P.D., Pescatello, L.S. Eur. J. Appl. Physiol. (2006) [Pubmed]
  12. NoBP, a nuclear fibroblast growth factor 3 binding protein, is cell cycle regulated and promotes cell growth. Reimers, K., Antoine, M., Zapatka, M., Blecken, V., Dickson, C., Kiefer, P. Mol. Cell. Biol. (2001) [Pubmed]
  13. Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. Foulkes, W.D., Campbell, I.G., Stamp, G.W., Trowsdale, J. Br. J. Cancer (1993) [Pubmed]
  14. Fibroblast growth factor 3, a protein with a dual subcellular fate, is interacting with human ribosomal protein S2. Antoine, M., Reimers, K., Wirz, W., Gressner, A.M., Müller, R., Kiefer, P. Biochem. Biophys. Res. Commun. (2005) [Pubmed]
  15. Induction of inner ear fate by FGF3. Vendrell, V., Carnicero, E., Giraldez, F., Alonso, M.T., Schimmang, T. Development (2000) [Pubmed]
  16. Evaluation of the tumorigenic and angiogenic potential of human fibroblast growth factor FGF3 in nude mice. Li, J.J., Friedman-Kien, A.E., Cockerell, C., Nicolaides, A., Liang, S.L., Huang, Y.Q. J. Cancer Res. Clin. Oncol. (1998) [Pubmed]
  17. Regulation of FGF-3 gene expression in tumorigenic and non-tumorigenic clones of a human colon carcinoma cell line. Galdemard, C., Yamagata, H., Brison, O., Lavialle, C. J. Biol. Chem. (2000) [Pubmed]
  18. Growth factors in progression of human esophageal and gastric carcinomas. Yoshida, K., Yasui, W., Ito, H., Tahara, E. Experimental pathology. (1990) [Pubmed]
  19. NH2-terminal cleavage of xenopus fibroblast growth factor 3 is necessary for optimal biological activity and receptor binding. Antoine, M., Daum, M., Köhl, R., Blecken, V., Close, M.J., Peters, G., Kiefer, P. Cell Growth Differ. (2000) [Pubmed]
  20. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer. Champème, M.H., Bièche, I., Hacène, K., Lidereau, R. Mod. Pathol. (1994) [Pubmed]
  21. Allelic loss from chromosome 11 in parathyroid tumors. Friedman, E., De Marco, L., Gejman, P.V., Norton, J.A., Bale, A.E., Aurbach, G.D., Spiegel, A.M., Marx, S.J. Cancer Res. (1992) [Pubmed]
  22. Stable and temperature-sensitive transformation of rat kidney epithelial cells suppresses expression of acidic fibroblast growth factor 1 but activates secretion of fibroblast growth factor 3 (int-2) and vascular endothelial growth factor. Zhang, G., Sato, J.D., Herley, M.T., Tsang, M.W., Ye, H., Liu, H., Ichimura, T., Yan, G., McKeehan, W.L., Stevens, J.L. Cell Growth Differ. (1994) [Pubmed]
  23. Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes. Holzmann, K., Kohlhammer, H., Schwaenen, C., Wessendorf, S., Kestler, H.A., Schwoerer, A., Rau, B., Radlwimmer, B., Döhner, H., Lichter, P., Gress, T., Bentz, M. Cancer Res. (2004) [Pubmed]
  24. Framework YAC contig anchored into a 3.2-Mb high-resolution physical map in proximal 11q13. Courseaux, A., Szepetowski, P., Fernandes, M., Serizet, C., Kawaguchi, Y., Grosgeorge, J., Perucca-Lostanlen, D., Shows, T.B., Todd, J.A., Nowak, N.J., Gaudray, P. Genomics (1997) [Pubmed]
  25. Co-overexpression of fibroblast growth factor 3 and epidermal growth factor receptor is correlated with the development of nonsmall cell lung carcinoma. Tai, A.L., Sham, J.S., Xie, D., Fang, Y., Wu, Y.L., Hu, L., Deng, W., Tsao, G.S., Qiao, G.B., Cheung, A.L., Guan, X.Y. Cancer (2006) [Pubmed]
  26. Nucleolar association of fibroblast growth factor 3 via specific sequence motifs has inhibitory effects on cell growth. Kiefer, P., Dickson, C. Mol. Cell. Biol. (1995) [Pubmed]
  27. Deletion and translocation of chromosome 11q13 sequences in cervical carcinoma cell lines. Jesudasan, R.A., Rahman, R.A., Chandrashekharappa, S., Evans, G.A., Srivatsan, E.S. Am. J. Hum. Genet. (1995) [Pubmed]
  28. Amplification of FGF-related genes in human tumors: possible involvement of HST in breast carcinomas. Theillet, C., Le Roy, X., De Lapeyrière, O., Grosgeorges, J., Adnane, J., Raynaud, S.D., Simony-Lafontaine, J., Goldfarb, M., Escot, C., Birnbaum, D. Oncogene (1989) [Pubmed]
  29. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Lammie, G.A., Fantl, V., Smith, R., Schuuring, E., Brookes, S., Michalides, R., Dickson, C., Arnold, A., Peters, G. Oncogene (1991) [Pubmed]
WikiGenes - Universities